A pharmaceutical composition comprising N1 {3-fluoro-4-[(6(methyloxy)-7- {[3-(4-morpholinyl)propyl] oxy)-4-Quinolinyl)oxy]phenyl)- N1 -(4 fluorophenyl)-1,1Cyclopropanedicarboxamide

Abstract

The present invention relates to a pharmaceutical composition for treating cancer in a patient comprising: a) a compound of formula A: or a pharmaceutically acceptable salt thereof, wherein R1-R4, p, and q are as defined; and (b) an erbB inhibitor that inhibits erbB-1 or erbB-2 or erbB-3 receptor or a combination thereof wherein the compound of formula A and the erbB inhibitor have a synergistic effect in inhibiting cell growth compared with the compound of formula A and the erbB inhibitor alone. The pharmaceutical composition of the present invention addresses a need in the art with the discovery of a combination therapy that shows evidence of being a more effective therapy than previously disclosed therapies